Wegovy approved in Canada to combat the risk of non-fatal heart attack – National

Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of a non-fatal heart attack or myocardial infarction in some adults, the Danish drugmaker said Wednesday.

According to Novo Nordisk, Wegovy has become the first approved treatment in Canada to address both obesity and the risk of heart-related disease in adults with established cardiovascular disease.

The European Union's health regulator recently backed the drug for reducing the risk of serious cardiovascular events and stroke in overweight or obese adults without diabetes.

Receive weekly health news

Receive the latest medical news and health information every Sunday.

Wegovy is also approved in the UK and US to lower the risk of serious heart problems or stroke in overweight and obese adults.

The drug, known chemically as semaglutide, has been approved in Canada as of 2021 to treat obesity.

4:17
Ozempic maker brings weight loss drug Wegovy to Canada